JEFFREY JONES: Open Payments
NPI 1669050159 · AUSTIN, TX. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$1,816 in 65 payments from 9 companies in 2025. Trend: 2023 $945 · 2024 $1,049 · 2025 $1,816
Food & beverage: $1,816
| Company | Payments | Amount |
|---|---|---|
| Gilead Sciences, Inc. | 19 | $510 |
| Madrigal Pharmaceuticals | 11 | $411 |
| Salix Pharmaceuticals, a division of Bausch Health US, LLC | 16 | $248 |
| Ipsen Biopharmaceuticals, Inc | 6 | $176 |
| Mirum Pharmaceuticals, Inc. | 1 | $134 |
| Novo Nordisk Inc | 2 | $129 |
| Intercept Pharmaceuticals, Inc. | 7 | $120 |
| Eton Pharmaceuticals, Inc. | 1 | $45 |
| ORPHALAN INC | 2 | $43 |
Products named: REZDIFFRA, XIFAXAN, IQIRVO, Livmarli, Wegovy, OCALIVA, GALZIN, CUVRIOR.
Industry payments across TX — which companies pay providers there.
